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Abstract
The non-motor features of Parkinson’s disease (PD) are increasingly being recognised. This review deals with the spectrum 
of sleep disorders associated with PD, which have a multifactorial aetiology and can significantly have an impact on the qual-
ity of life of patients and their carers. Some sleep disorders represent a prodromal phase of PD, with REM sleep behaviour 
disorder (RBD) being of particular interest in this regard, whereas others become more common as the disease advances. 
Understanding the pathophysiology of these sleep disturbances will hopefully lead to new treatment opportunities in the 
future. The recent discovery of the glymphatic system for removal of waste products from the brain has also raised the pos-
sibility that sleep disruption may cause or accelerate the underlying disease process.
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Introduction
Parkinson’s disease (PD) affects 1–2% of adults aged over 
65 years and is the second most common degenerative brain 
disorder. It has long been diagnosed based on its cardinal 
motor features: bradykinesia, rigidity and tremor. More 
recently, the prevalence and extent of non-motor features 
in PD has come to be recognised. These non-motor mani-
festations are varied and include dementia, mood disorders, 
autonomic disturbances, pain and sleep dysfunction [54]. 
Some of these non-motor features can appear prior to PD 
motor features. They can have marked effects on quality of 
life and even patient safety (such as increased risk of injury 
and accidents due to cognitive problems and excessive day-
time sleepiness) [10, 42]. The previous under-appreciation 
of non-motor features in PD was probably a combination of 
under-reporting of symptoms from patients, as well as a lack 
of awareness from their physicians [18].
In the PRIAMO study, Barone et al. found sleep disorders 
to be the second most prevalent non-motor complaint in a 
large cohort of 1072 PD patients, affecting 64% of patients 
across the entire disease spectrum [3].
This review will discuss the sleep disturbances associated 
with PD, with particular emphasis on management options 
and research priorities. It is not intended to be an exhaustive 
review on the topic [49, 64]. Instead, we will concentrate on 
topics where there have been recent advances that may lead 
to an improved understanding or new therapeutic approach 
to sleep dysfunction in PD.
The anatomy and function of sleep
Physiologically, sleep can be divided into rapid eye move-
ment (REM) and non-rapid eye movement (NREM) sleep. 
NREM constitutes the majority of sleep and can be further 
sub-divided into three stages (N1, N2 and N3), with depth of 
sleep and its restorative function increasing from N1 to N3. 
The remainder of the night is accounted for by REM sleep. 
The stages run cyclically throughout the night, with blocks 
of slow wave sleep getting shorter as the night goes on. The 
proportion of slow wave sleep reduces with ageing.
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The body’s control of sleep is dependent on the deli-
cate balance between sleep–wake homeostasis and circa-
dian rhythms. The suprachiasmatic nucleus (SCN), a brain 
region located in the anterior hypothalamus, acts as the 
body’s master clock and coordinates a robust 24-h rhythm 
that incorporates sleep and other key bodily functions. In 
turn, the SCN receives input from external stimuli (such as 
light cues, motor activity and feeding patterns) and exerts its 
influence through a variety of neural and hormonal mecha-
nisms. “Clock genes” are vital components within the cel-
lular machinery that drive the circadian signal in every cell 
in the body via auto-regulatory feedback loops [63].
There are a number of theories regarding why we sleep: to 
enable cellular processes to recover from the day (e.g. oxida-
tive stress), to facilitate the clearance of waste proteins from 
the brain, and to optimise learning and memory. Initially 
postulated by Tononi and Cirelli, the ‘synaptic homeostasis 
hypothesis’ proposes that sleep promotes synaptic downs-
caling in the brain following the strengthening of synaptic 
connections during wakefulness in response to new infor-
mation [60]. Studies have since highlighted the complexity 
of this system, with various brain regions, sleep stages and 
genes being implicated. In 2017, Li et al. [36] highlighted 
the importance of REM sleep on synaptic spine formation 
and pruning. The role of sleep in synaptic plasticity and 
memory consolidation has been reviewed elsewhere [52].
Spectrum of sleep disorders in PD
Sleep disorders in PD encompass insomnia (difficulties with 
sleep initiation and/or sleep maintenance), parasomnias [par-
ticularly REM sleep behaviour disorder (RBD)], excessive 
daytime sleepiness (EDS), periodic limb movements of sleep 
(PLMS), restless leg syndrome (RLS) and obstructive sleep 
apnoea (OSA). These disorders can be directly related to 
underlying disease pathology, secondary to symptoms of the 
disease, or secondary to medication side effects.
Up to 90% of PD patients experience some form of sleep 
dysfunction [39]. Studies have used a variety of validated 
sleep scales to demonstrate sleep problems in PD patients: 
Parkinson’s Disease Sleep Scale 2 (PDSS-2), Scales for 
Outcomes in Parkinson’s Disease–Sleep (SCOPA-SLEEP), 
Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepi-
ness Scale (ESS). Most of these scales evaluate symptoms 
in the recent past (over the prior 1–4 weeks), with questions 
designed to probe different PD symptoms that might influ-
ence sleep. In doing so, these questionnaires not only assess 
the presence and severity of sleep problems but can also 
help to identify their cause and point towards suitable man-
agement strategies. The advantages and disadvantages of 
specific sleep questionnaires, both generic and PD-specific 
ones, have been reviewed elsewhere [34].
Peeraully et al. performed a systematic review on poly-
somnography case–control studies in PD [48]. Compared to 
controls, PD patients typically reported an increased number 
of nocturnal awakenings (classified as a period of wakeful-
ness of over 15 s) and had shorter sleep time. A number of 
other studies have shown reduced sleep efficiency, increased 
sleep latency and reduced REM sleep, but the data are more 
heterogeneous.
EDS is a feeling of sleepiness that impairs alertness and 
the ability to remain awake. It can result in difficulties with 
activities of daily living and cause patient safety issues. 
This includes an increased risk of injury and accidents: one 
questionnaire study reported that 11% of 5210 PD patients 
with a driving license had caused a road traffic accident and 
these individuals were more likely to have a higher ESS 
score [42]. The ESS is a convenient method of assessing 
daytime sleepiness, with scores ranging from 0–24 (> 10 
generally considered to be pathological). In a study of 118 
PD patients, Breen et al. found that 49% of PD patients had 
an ESS score > 10 [7]. Similar figures have been reported by 
other studies, with prevalence rates even higher in those PD 
patients with dementia [6]. EDS has been shown to predate 
a diagnosis of PD in some studies [1, 19]. EDS can also be 
assessed using the multiple sleep latency test (MSLT), with 
sleep latency less than 5 min considered pathological. Some 
PD patients experience more abrupt “sleep attacks” which 
have a more narcolepsy-like phenotype.
RLS and PLMS often co-exist and are highly prevalent in 
PD [14, 71], with RLS affecting around 30% of patients [39]. 
RLS is characterised by a marked urge to move (particu-
larly the legs), typically in the evening and during periods 
of rest and inactivity, which is relieved by moving and only 
returns when the movement stops. Dopamine dysfunction, 
and in some cases iron deficiency, have been implicated in 
the pathophysiology of RLS [13, 46]. There is also a link 
between RLS and other comorbidities such as renal disease, 
type 2 diabetes mellitus, migraine and neuropsychiatric dis-
orders [5].
PLMS are typically a repetitive limb movement, often 
dorsiflexion of the foot along with partial hip and knee flex-
ion. They can occur in the general population [45] but are 
present in up to 87% of individuals with RLS [43].
Breathing disorders are a recognised feature of PD. In 
1984, Vincken et al. used EMG and laryngoscopy to identify 
intermittent rhythmic or irregular flow oscillations (or even 
complete obstruction) of the glottis and supraglottic struc-
tures in patients with extrapyramidal disease [66]. Preva-
lence figures for OSA in PD are varied, with most studies 
being small and involving patients with co-existing sleep 
disorders. Cochen De Cock et al. studied 100 PD patients, 50 
of whom had been referred due to EDS and 50 with no prior 
sleep disorder diagnosis. They found 27% of PD patients had 
sleep apnoea (17% mild–moderate, 10% severe) compared 
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to 40% in matched controls [15]. On the other hand, Trotti 
et al. carried out overnight polysomnography on 55 patients 
with idiopathic PD for 3 consecutive nights and found no 
difference in the rates of OSA between PD patients and con-
trols [61].
Aetiology of sleep disorders in PD
The pathophysiology of sleep disorders in PD is likely to 
be multifactorial and secondary to PD nocturnal features, 
underlying neuronal damage, and side effects of PD medi-
cations [11]. This varied aetiology is particularly evident 
with insomnia, where sleep disruption can be caused by dif-
ficulty in moving in bed at night (often due to nocturnal 
wearing off), tremor, neuropsychiatric symptoms or pain. 
Whilst some of these symptoms can be remedied with symp-
tomatic medications, some patients continue to experience 
sleep issues.
Changes in sleep architecture due to underlying dam-
age to key regions involved in sleep regulation are likely to 
account, at least in part, for the difficulties that PD patients 
experience in getting to and staying asleep. Indeed, several 
of these brain regions (e.g. locus coeruleus, hypothalamus, 
amygdala, thalamus, pedunculopontine nucleus) have been 
shown to be affected by Lewy body pathology in post-mor-
tem studies [30].
Alterations in hormonal rhythms have been implicated 
in causing PD-related sleep dysfunction. Cortisol and mela-
tonin output are controlled by the SCN and show diurnal 
variation, with a cortisol peak early in the morning and a 
melatonin peak in the evening. It has been demonstrated that 
these hormonal rhythms are disrupted in PD patients (and 
other neurodegenerative diseases such as Alzheimer’s and 
Huntington’s disease). Videnovic et al. found lower levels of 
melatonin (reduction in amplitude and 24-h area under the 
curve) in 20 PD patients compared to 15 age-matched con-
trols in a carefully controlled study taking into account light 
exposure, food intake and level of physical activity [62]. 
This difference was even more pronounced in patients with 
EDS. Similar findings were reported by Breen et al. who 
reported reduced 24-h melatonin output in 30 early stage PD 
patients versus 15 age-matched controls, along with a corre-
lation between melatonin AUC and proportion of slow wave 
and REM sleep [8]. A subsequent study by the same group 
showed that hypothalamic grey matter volume was signifi-
cantly reduced in PD patients and associated with decreased 
melatonin output, suggesting a link between degenerative 
changes in the hypothalamus and sleep disruption in PD [9].
Altered sleep architecture and disrupted sleep patterns 
may directly lead to EDS, however, there is also a link 
between dopaminergic medications (particularly dopamine 
agonists) and EDS [27, 47]. The use of dopamine agonists 
has been shown to contribute to worsening of ESS scores 
[24], as has non-tremor dominant motor phenotype and com-
mon variations in the catechol-O-methyltransferase gene 
involved in dopamine breakdown [7].
Hypocretin (also known as orexin) is produced by the 
hypothalamus and acts to promote wakefulness. Deficits in 
this signalling system have previously been linked to nar-
colepsy and cataplexy. It has also been demonstrated that 
there is a loss of hypocretin neurons in individuals with PD. 
In a study by Thannickal et al., the hypothalami of 11 PD 
patients and 5 healthy control patients were examined and 
a reduction in hypocretin neurons was seen in PD patients, 
with more marked reduction in advanced disease [59]. 
Fronczek et al. studied the brain tissue of nine late-stage PD 
patients and found an almost 50% reduction in total hypocre-
tin neurons in the prefrontal cortex and hypothalamus com-
pared to 16 control subjects, alongside reduced hypocretin 
concentration in the ventricular cerebrospinal fluid (CSF) 
[17]. Wienecke et al. studied spinal CSF hypocretin levels 
in ten early and treatment naive PD patients, ten advanced 
PD patients and ten age-matched control subjects. Whilst 
a downward trend in hypocretin levels was noted between 
early and advanced patients, no statistically significant 
between-group differences were found [67]. However, in 
two patients with advanced PD in this study, a second CSF 
hypocretin measurement 4–5 years later showed a reduction 
over time, suggesting a progressive loss of hypocretin with 
advancing disease.
REM sleep behaviour disorder
REM sleep behaviour disorder (RBD) is one of the most 
studied sleep phenomena in PD, owing to the strong link 
between RBD and α-synucleinopathies. RBD occurs when 
individuals lose the usual muscle atonia associated with 
REM sleep, leading to dream enactment behaviours (which 
can be simple or complex movements) and/or vocalisations. 
The dreams experienced are usually vivid and often unpleas-
ant or frightening. These behaviours should be confirmed 
by polysomnography to make a definitive RBD diagnosis.
The locus coeruleus/subcoeruleus in the brainstem, which 
is equivalent to the sublaterodorsal tegmental nucleus in rats, 
is involved in maintaining REM atonia through inhibitory 
projections to spinal motor neurons. Garcia et al. showed 
that there is a role for the glutamate neurones in the rat sub-
laterodorsal tegmental nucleus in generating muscle atonia 
in sleep [20]. When glutamate transmission was reduced 
through inactivation of the glutamate transporter gene 
SLC17A6, sleep-induced muscle atonia was diminished 
and there was an increase in motor activity during sleep. 
In humans, a neuromelanin-sensitive MRI study demon-
strated decreased signal intensity within the locus coeruleus/
 Journal of Neurology
1 3
subcoerulus and a corresponding increase in muscle tone 
during sleep in those individuals with RBD [22].
In the general population, “idiopathic” RBD has a preva-
lence of 0.38–1.15% [12, 31]. Over 80% of individuals with 
RBD go on to develop an overt α-synucleinopathy [either 
PD, multiple system atrophy (MSA) or dementia with Lewy 
bodies (DLB)], and RBD has been shown to predate the 
onset of motor symptoms by several decades in some indi-
viduals [53]. In other words, RBD is a strong prodromal 
marker of these diseases. In the largest study to date, Pos-
tuma et al. found a phenoconversion rate of 6.3% per year 
for individuals with idiopathic (or rather isolated) RBD [51]. 
A number of clinical and biological markers were identified 
that increased the risk of earlier phenoconversion such as 
older age, mild motor impairment, olfactory deficits, auto-
nomic dysfunction (e.g. erectile dysfunction, constipation) 
and abnormal dopamine transporter imaging.
In the future, individuals with RBD may be an attrac-
tive patient population to test new disease-modifying drug 
therapies when they become available. However, it is worth 
noting that PD patients with RBD tend to exhibit a more 
severe disease phenotype with increased falls, reduced 
responsiveness to dopaminergic drugs and increased non-
motor features (such as cognitive impairment, constipation 
and dizziness) [4].
Less commonly, RBD can arise in individuals with struc-
tural brain lesions (such as brainstem stroke or inflammatory 
lesions), Machado–Joseph disease (SCA-3), autoimmune 
brain diseases (such as anti-IgLON5 disease) and other 
pathologies. Some medications, in particular antidepressants 
such as selective serotonin reuptake inhibitors, have been 
noted to exacerbate or even trigger RBD [50]. It is unclear 
if RBD seen in these individuals is a pure side effect of the 
medication, or, more likely, if these medications unmask 
an underlying susceptibility in people at risk of developing 
brain disease in the future [50].
Glymphatic system
The brain lacks an intrinsic lymphatic system. Instead, it 
depends upon the CSF, interstitial fluid and water trans-
port (facilitated by aquaporin 4 [AQP4] channels) to clear 
waste proteins from the brain. Due to this reliance on glial 
cells, Iliff et al. termed this the “glymphatic system” [29]. 
They studied the accumulation of β-amyloid in the brains of 
healthy mice, alongside AQP4 gene knockout mice. Where 
the channel was deleted, there was a marked decrease (55%) 
of β-amyloid clearance. A subsequent study showed the role 
of this system in the clearance of tau [28].
Following this, the role for sleep in the efficient func-
tioning of the glymphatic system was demonstrated using 
radiolabeled β-amyloid in awake, asleep and anaesthetised 
mice [69]. β-amyloid was cleared twice as quickly in asleep 
and anaesthetised mice than in awake mice, which was 
reported to be due to an increase in the interstitial space 
during sleep, allowing for greater exchange of fluids (and 
thus waste proteins).
Complementary findings have now been reported in 
humans. A study from Shokri-Kojori et al. used positron 
emission tomography (PET) in 20 healthy individuals to 
show that one night of sleep deprivation was sufficient to 
increase the burden of β-amyloid in the hippocampus and 
the thalamus [55]. Similarly, Lucey et al. sampled CSF 
β-amyloid in individuals with normal sleep, induced sleep 
(with sodium oxybate) and sleep deprivation. This study 
showed a 25–30% increase in β-amyloid in sleep-deprived 
individuals [37]. Holth et al. sampled CSF β-amyloid, tau 
and α-synuclein in a group of individuals after normal sleep 
and 1 night of sleep deprivation and found a 30% increase 
in CSF β-amyloid and 36% increase in α-synuclein follow-
ing sleep deprivation [26]. It is unknown whether increased 
production or reduced clearance of waste proteins is respon-
sible for this.
Based on these findings, it has been proposed that the 
glymphatic system may play a key role in the removal of 
toxic proteins from the brain (particularly during sleep). Pre-
vious research has shown a decrease in the activity of the 
glymphatic system with advancing age [32].
Sleep and circadian disruption as a risk 
factor for PD?
The discovery of the glymphatic system has added to the 
hypothesis that sleep and circadian disruption may cause, or 
accelerate, age-related brain diseases. Other mediators of the 
relationship between sleep and brain health may include oxi-
dative stress, inflammation, blood brain–barrier integrity and 
biological ageing. Prospective studies have demonstrated a 
link between sleep disruption and incident cognitive impair-
ment [70], but there is now emerging evidence related to PD.
A recent study by Sohail et al. suggested that sleep distur-
bances other than RBD may predate the onset of PD motor 
symptoms. 269 older adults without PD were assessed for 
sleep fragmentation during their life (using wrist-worn actig-
raphy recording for 7 consecutive days) and followed up 
until death. The median time between actigraphy data and 
death was 1.4 years. The study found that individuals with 
sleep fragmentation had a higher presence of Lewy body 
pathology and substantia nigra cell loss on post-mortem 
examination [56].
Lysen et al. prospectively assessed subjective sleep qual-
ity as part of a nested cohort study of 7726 individuals 
within the Rotterdam study. Poor sleep quality and shorter 
duration of sleep were associated with an increased risk of 
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parkinsonism and PD over the next 2 years, with the strength 
of this relationship attenuating over longer follow-up. Like 
the study from Sohail et al., the authors concluded that sleep 
disturbances may be a prodromal feature of PD rather than 
a causal factor per se [38], however further research involv-
ing large cohorts and a range of sleep (both subjective and 
objective) and brain health measures are needed.
In a recent study by Noyce et al., mendelian randomi-
sation was used to highlight a potential causal association 
between being a “morning person” and subsequent increased 
risk of developing PD [44], although the precise mechanisms 
behind this are not clear.
Therapeutic approaches
Management of sleep disorders should begin with simple 
measures, aiming for optimum management of motor symp-
toms and ensuring good sleep hygiene [64]. These practices 
include advice on regularising bed times and light exposure, 
avoiding wake-promoting substances (such as nicotine and 
caffeine) and medications later in the day, avoiding pro-
longed time in bed whilst awake, and avoiding exercising 
later in the day [58, 72].
Given the blunted melatonin rhythms observed in PD 
patients, melatonin supplementation should be considered 
for the treatment of insomnia. Dowling et al. assessed the 
efficacy of melatonin administration for sleep disturbances 
in 40 PD patients [16]. Although no significant differences 
were seen when 5 mg melatonin was compared to placebo, 
a small (but statistically significant) increase in sleep time 
was noted with 50 mg melatonin. In a similar study, Medei-
ros et al. randomised 18 patients to receive either 3 mg 
melatonin or placebo [41]. Again, no significant differences 
were found between the groups. Whilst these studies did not 
report substantial objective benefit from melatonin therapy, 
patients reported subjective benefits. It should be noted that 
these were relatively small studies of heterogenous popula-
tions with a mixture of sleep disturbances.
Current treatment options for RBD involve supportive 
management including altering the sleeping environment to 
make it safer (e.g. moving furniture and placing cushions 
next to the bed). Melatonin and clonazepam are the mainstay 
of pharmacological management [33, 35], although a recent 
study found no overall benefit in RBD symptoms using pro-
longed release melatonin compared to placebo [23].
Management of RLS includes iron replacement in indi-
viduals with proven iron deficiency and avoidance of medi-
cations known to exacerbate RLS (such as antidepressants, 
antihistamines and dopamine antagonists). If additional 
treatment is required, dopamine agonists are commonly 
started, with consideration given to the possibility of aug-
mentation (a poorly understood phenomenon that occurs 
with long-term dopaminergic therapy characterised by more 
severe symptoms occurring earlier in the day). Alpha-2 delta 
ligands (such as pregabalin) are now considered an alterna-
tive first-line treatment [2], but the initial drug of choice 
should be carefully chosen according to symptomatology 
and the individual needs [21, 68].
Part of the control of circadian rhythmicity comes from 
input from specialised retinal ganglion cells that receive 
light input and assist in entraining the sleep–wake cycle. 
These pathways have been shown to be damaged in PD, with 
evidence of dopaminergic retinal degeneration [25]. Studies 
have also indicated that individuals with PD are exposed to 
less natural light throughout the day, presumably due to the 
impact of their disease on daily functioning [57]. It is also 
likely that even in PD patients receiving normal levels of 
natural light, damage to the SCN may affect the central cir-
cadian pacemaker. To counteract this, it has been proposed 
that light therapy could be beneficial. Videnovic et al. stud-
ied the effect of bright light therapy (10,000 lx) compared 
to a control group of dim-red light (< 300 lx) in PD patients. 
Light therapy was delivered in two 1-h sessions every day 
for 2 weeks, resulting in self-reported benefits in sleep qual-
ity, ease of falling asleep and improved disease severity (as 
assessed using the Unified Parkinson’s Disease Rating Scale 
(UPDRS)). There was also decreased sleep latency and an 
overall increase in physical activity on actigraphy monitor-
ing. Some benefits were noted in the dim-red light therapy 
group as well, which was suggested to be related to the daily 
structure imposed by the regular light therapy [65]. Martino 
et al. carried out a retrospective study on individuals with 
PD who had received timed light therapy (3000–4000 lx) for 
a 1-h period 1–4 h before sleep [40]. Light therapy improved 
insomnia and reduced nocturnal movement. These studies 
have proven that light therapy is safe and feasible to deliver. 
Larger studies are now required to prove its therapeutic effi-
cacy, as well as decide upon optimum timings and intensities 
of light therapy delivery.
Finally, the orexin signalling system is a promising treat-
ment target for some PD-related sleep disorders. The dual 
orexin receptor antagonist suvorexant has been approved as 
a treatment for primary insomnia. Studies are underway to 
assess its benefit in neuropsychiatric and neurodegenerative 
disorders including Parkinson’s disease (ClinicalTrials.gov 
Identifier: NCT02729714).
Conclusion
Sleep is of great interest in the field of PD and neurode-
generative diseases for a number of reasons. First, it is a 
common symptom that has an impact on quality of life 
and can influence daytime functions (including cognitive 
abilities). Second, there are some aspects of sleep (such as 
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RBD) which may provide a window into the early prodro-
mal period and enable potentially therapeutic interventions 
to target this patient population. Third, there is emerging 
evidence that sleep directly influences brain health and 
could even be a risk factor for the development and pro-
gression of age-related brain diseases. By understanding 
the full spectrum of sleep disorders and their causes, we 
will hopefully be able to improve quality of life in patients 
and potentially influence the course of their disease.
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